



**FOUNDATION KIND BETER
AT DEN HAAG**

Annual Report 2025



Stichting Kind Beter • 2596 CC Den Haag • The Netherlands
+31(0)6-21513762 • kindbeter@ziggo.nl • KVK nummer/Chamber of Commerce: 71725261
RSIN/Tax number: 858824693 • kindbeter.nl



CONTENTS

	Page
AUDITOR'S REPORT	
1 Engagement	3
2 Compilation report	3
1 MANAGEMENT REPORT	4
FINANCIAL STATEMENTS	
1 Balance sheet as at December 31, 2025	7
2 Profit and loss account over 2025	8
3 Notes to the financial statements	9
4 Notes to the balance sheet as of December 31, 2025	10
5 Notes to the profit and loss account 2025	11





To the management of
Foundation Kind Beter
Brusselselaan 12
2587 AH The Hague

Reference

19110

Processed by

WKO

Date

June 24, 2026

Dear management,

We hereby send you the report regarding the financial statements for the year 2025 of the foundation.

1 ENGAGEMENT

In accordance with your instructions we have compiled the annual account 2025 of the foundation, including the balance sheet with counts of € 39,844 and the profit and loss account with a result of € 1,776.

2 COMPILATION REPORT

Introduction

In accordance with your instructions we have compiled the financial statements 2025 of Stichting Kind Beter in Den Haag, which comprise the balance sheet as at December 31, 2025, the profit and loss account for 2025 and the notes.

Management's responsibility

The distinctive feature of a compilation engagement is that we compile financial information based on information provided by management of the entity. Management is responsible for the accuracy and completeness of the information provided and the financial statements based thereon.

Confirmation

Based on the information provided to us, we have compiled the financial statements using the accounting policies as included in Part 9 of Book 2 of the Dutch Civil Code.





Stichting Kind Beter, Den Haag

1 MANAGEMENT REPORT

Background:

In 2012, our son Fenn was born. At first, he appeared to be a typical child, but it soon became clear that he had a rare disorder. The genetic mutation affecting the FOXP1 gene had only recently been identified, and no fundamental research had yet been conducted into its cause or potential treatment. Today, approximately 500 children worldwide have been diagnosed with this condition. The severity and manifestation of the syndrome vary from child to child.

Together with Leiden University Medical Center (LUMC), a research program was defined. To make this possible, funding needed to be secured. Stichting Kind Beter (Better Child Foundation) was established for this purpose.

At the end of 2018, we began developing our website in both Dutch and English. Shortly thereafter, we successfully obtained ANBI status (Public Benefit Organization status in the Netherlands). In the years that followed, Stichting Kind Beter actively raised funds to support scientific research into FOXP1 syndrome. Thanks to the contributions of donors, sponsors, and charitable funds, a research program was established and carried out in collaboration with LUMC.

In 2024, the first phase of the research was completed, marking an important milestone with the successful development of organoids by LUMC. These miniature models of human tissue enable researchers to better understand disease mechanisms and provide an important foundation for future research into potential treatments for FOXP1 syndrome.

In addition, together with Prof. Dr. Willeke van Roon (LUMC) and an international consortium, we secured a €1.3 million grant for follow-up research (the HOPE Project). This funding is not administered through Stichting Kind Beter, but it enables the further development of advanced organoid technology. The consortium consists of LUMC, Radboud University Medical Center, PimBio BV, Heidelberg University, and the foundations Kind Beter and Proefdiervrij.

Within this project, advanced brain organoids are being used to test both existing and newly developed medicines for their potential effectiveness in treating symptoms of FOXP1 syndrome. This innovative approach offers promising opportunities to identify treatments that may improve patients' quality of life.

In June 2025, Stichting Kind Beter made a significant contribution through the successful organization of the international FOXP1 Conference. During this event, researchers, physicians, patients, and families from around the world came together to share knowledge, discuss research findings, and foster new collaborations. The conference further strengthened the international FOXP1 network and created new opportunities for future research.



Stichting Kind Beter, Den Haag

Another key focus in 2025 was the preparation of the next phase of research. Together with our scientific partners, plans were developed for follow-up studies, and initial preparations were made for new grant applications. In doing so, we are building on the achievements of recent years and creating the conditions necessary to further accelerate research into effective treatments for FOXP1 syndrome.

Stichting Kind Beter also continues to serve as a connecting force, in collaboration with the international FOXP1 patient association, bringing together patients, parents, caregivers, and researchers in the Netherlands, Belgium, and beyond.

Vision:

We believe that, with the right effort, people can be inspired to contribute to finding solutions for rare diseases.

Ambition:

To enable scientific research that leads to effective treatments and, ultimately, a cure for FOXP1 syndrome.

Objectives:

Primary Objectives:

- " To fund research into the causes of and potential cures for the rare genetic disorder FOXP1 syndrome;
- " To finance potential medical treatments and medications aimed at curing or treating FOXP1 syndrome.

Secondary Objectives:

- " To identify and screen related disorders that may benefit from further analysis arising from this research;
- " To connect patients, parents, caregivers, and scientists.

General:

To develop and maintain relevant relationships that contribute to achieving the above objectives.

Organization and Governance:

The foundation had no employees. The composition of the Board has remained unchanged since 2018.

Board members serve on a voluntary basis and receive no remuneration. We have strengthened our fundraising activities with the support of two volunteer funding specialists, Caroline Valk and Sylvia Bos. In addition, a parent couple of a child with FOXP1 syndrome, Tom Wesseling and Annemiek Linn, actively support the foundation's work.

Closing Remarks:

In 2025, we once again witnessed how essential collaboration between families, researchers, healthcare professionals, and volunteers is in advancing research into FOXP1 syndrome. The results achieved so far give us confidence for the future and reinforce our belief that further progress is possible.

We remain committed to our ultimate goal: advancing research into FOXP1 syndrome and related genetic disorders. Because every child deserves the chance to get better.

Board of Stichting Kind Beter:

Chairman - André de Koning
Secretary - Esther Kloosterman
Treasurer - Wilko Korving



FINANCIAL STATEMENTS





Stichting Kind Beter, Den Haag

1 BALANCE SHEET AS AT DECEMBER 31, 2025

(before appropriation of results)

		December 31, 2025		December 31, 2024	
		€	€	€	€
ASSETS					
Current assets					
Cash and cash equivalents	(1)		39,844		38,068

TOTAL ASSETS

39,844

38,068

Compilation report issued



EQUITY AND LIABILITIES

Capital

(2)

December 31, 2025		December 31, 2024	
€	€	€	€

39,844



38,068

TOTAL LIABILITIES

39,844

38,068

Compilation report issued





Stichting Kind Beter, Den Haag

2 PROFIT AND LOSS ACCOUNT OVER 2025

		2025		2024	
		€	€	€	€
Donations	(3)		14,165		9,159
Expenses					
Other operating expenses	(4)		12,389		257
Result			<u>1,776</u>		<u>8,902</u>
Taxation on result from general operations			-		-
Result			<u><u>1,776</u></u>		<u><u>8,902</u></u>



Stichting Kind Beter, Den Haag

3 NOTES TO THE FINANCIAL STATEMENTS

Activities

The foundation of Stichting Kind Beter was established by notarial deed on 23 May 2018. The objectives of the Foundation are:

Expanding knowledge with regard to FOXP1 in particular and other related genetic abnormalities. To fund related research and development of gene targeted therapies for FOXP1 and talented syndromes.

GENERAL PRINCIPLES FOR THE PREPARATION OF THE ANNUAL ACCOUNTS

The annual accounts have been prepared in accordance with Guideline 650 for fundraising institutions of the Dutch Council for Annual Reporting.

The annual accounts have been prepared based on the historical cost. Valuation of assets and liabilities and determination of the result takes place under the historical cost convention. Income and expenses are allocated to the year to which they relate. Profits are only included insofar as they have been realized on the balance sheet date. Liabilities and possible losses that originate before the end of the reporting year are taken into account if they have become known before the preparation of the annual accounts.

ACCOUNTING PRINCIPLES APPLIED TO THE VALUATION OF ASSETS AND LIABILITIES

Cash and cash equivalents

The cash is valued at face value. If cash equivalents are not freely disposable, then this has been taken into account in the valuation.

PRINCIPLES FOR THE DETERMINATION OF THE RESULT

General

The result is defined as the difference between the revenue from goods delivered and services performed on one hand and, on the other hand, the costs and expenses for that year, valued at historical costs.

Expenses general

Costs are determined on a historical basis and are attributed to the reporting year to which they relate.



Stichting Kind Beter, Den Haag

4 NOTES TO THE BALANCE SHEET AS OF DECEMBER 31, 2025

ASSETS

	<u>12/31/2025</u>	<u>12/31/2024</u>
	€	€
1. Cash and cash equivalents		
ING Bank N.V.	39,844	38,068

The cash equivalents are at free disposal.

EQUITY AND LIABILITIES

2. Equity

Reconciliation company capital

Consolidated capital	<u>39,844</u>	<u>38,068</u>
----------------------	---------------	---------------



Stichting Kind Beter, Den Haag

5 NOTES TO THE PROFIT AND LOSS ACCOUNT 2025

	2025	2024
	€	€
3. Donations		
Donations	14,165	9,159

Staff

During the 2025 financial year the company had no employees.

4. Other operating expenses

Sales and distribution expenses	11,288	-
General expenses	1,101	257
	<u>12,389</u>	<u>257</u>

Sales and distribution expenses

Contribution toward the costs of the international FOXP1 meeting in IJmuiden

	<u>11,288</u>	<u>-</u>
--	---------------	----------

General expenses

Consultancy fees	812	-
Bank charges	289	257
	<u>1,101</u>	<u>257</u>